000 01229 a2200349 4500
005 20250514183025.0
264 0 _c20041208
008 200412s 0 0 eng d
022 _a0041-1345
024 7 _a10.1016/j.transproceed.2004.01.059
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aAugustine, J J
245 0 0 _aExperience with everolimus.
_h[electronic resource]
260 _bTransplantation proceedings
_cMar 2004
300 _a500S-503S p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aCreatinine
_xblood
650 0 4 _aCyclosporine
_xtherapeutic use
650 0 4 _aDrug Therapy, Combination
650 0 4 _aEverolimus
650 0 4 _aHumans
650 0 4 _aImmunosuppressive Agents
_xchemistry
650 0 4 _aKidney Transplantation
_ximmunology
650 0 4 _aLymphocyte Activation
_xdrug effects
650 0 4 _aSirolimus
_xanalogs & derivatives
650 0 4 _aT-Lymphocytes
_ximmunology
650 0 4 _aTime Factors
650 0 4 _aTransplantation Immunology
700 1 _aHricik, D E
773 0 _tTransplantation proceedings
_gvol. 36
_gno. 2 Suppl
_gp. 500S-503S
856 4 0 _uhttps://doi.org/10.1016/j.transproceed.2004.01.059
_zAvailable from publisher's website
999 _c14758560
_d14758560